JMIR Mhealth Uhealth. 2025 May 20;13:e53586. doi: 10.2196/53586.
ABSTRACT
BACKGROUND: Anticoagulation management is important in preventing complications in patients undergoing cardiac valve replacement. The development of mobile apps offers new opportunities for the management of long-term anticoagulants. However, there is a lack of randomized controlled trials evaluating the effectiveness, safety, cost-effectiveness, and user demand for internet-based anticoagulation management.
OBJECTIVE: This study aimed to evaluate the efficacy, safety, and cost-effectiveness of a 3-month warfarin dose adjustment mobile app Alfalfa compared to offline management in patients postcardiac valve replacement. We also explored the app’s feasibility on user satisfaction and demand.
METHODS: This study was a randomized controlled trial with assessments conducted at baseline and at a 3-month follow-up. Participants were eligible if they had been on warfarin therapy for at least 3 months, received warfarin management either through the Alfalfa app or through pharmacist-led anticoagulation outpatient clinic visits, consented to regular follow-ups, and had not experienced serious bleeding or thrombotic events in the 3 months before warfarin treatment. A P value of ≤.05 was considered statistically significant.
RESULTS: A total of 405 participants were included in the analysis. The time in therapeutic range was significantly higher in the Alfalfa app group than in the offline group (66.46% vs 46.65%, P<.001). Participants in the Alfalfa app group had a higher monitoring frequency (8.14 vs 4.47, P<.001) and a greater percentage of international normalized ratio values within the target range (896/1660, 53.98% vs 346/899, 38.49%; P<.001) than those in the offline group. In addition, the Alfalfa app group exhibited lower rates of subtherapeutic (235/1660, 14.16% vs 152/899, 16.91%; P<.05) and extreme subtherapeutic international normalized ratio values (273/1660, 16.45% vs 186/899, 20.69%; P<.05) than the offline group. However, the incidence of minor bleeding was higher in the Alfalfa app group (12/204, 5.9% vs 3/201, 1.5%; P=.02). In terms of cost-effectiveness, the Alfalfa app group had a significantly lower average cost per test (42.37 vs 78.3, P<.001), average time per test (47.42 vs 90.74, P<.001), and cost-effectiveness ratio (385.9 vs 662.9) than the offline group. A total of 86 participants completed the satisfaction questionnaire, and the vast majority of participants expressed high levels of satisfaction with the Alfalfa App, while also providing further suggestions for improvement.
CONCLUSIONS: The integration of “Internet+Pharmacy Care” using the Alfalfa App can improve the effectiveness of warfarin anticoagulation management in patients following heart valve surgery. The Alfalfa app provides a more efficient, secure, and cost-effective solution to warfarin management than traditional offline methods.
PMID:40393057 | DOI:10.2196/53586
